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Abstract  A  28-year-old  neuromuscular  patient  chronically  treated  with  nocturnal  noninvasive
ventilation  developed  pulmonary  lobar  atelectasis  and  daytime  hypoxemia.  Twenty  four-hour
5 L/min  oxygen  was  begun,  while  mechanical  cough  assist  aids  were  applied  for  seven  days.  In
the following  three  days,  treatment  with  nebulized  Dornase  alpha  (rhDNase)  b.i.d.  was  tested,
without any  signiﬁcant  improvement.  On  11  and  13th  days  rhDNase  was  instilled  by  ﬂexible  bron-
choscopy.  A  rapid  resolution  of  the  atelectasis  was  observed  with  relief  of  hypoxemia,  without
signiﬁcant  side  effects.  On  day  16  the  patient  was  discharged  without  oxygen  requirements.  In
non-intubated  neuromuscular  patients  with  atelectasis  who  do  not  respond  successfully  to  non-
invasive treatments  intrabronchial  instillation  of  rhDNase  may  safely  help  to  improve  airway
clearance.
© 2012  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
PALAVRAS-CHAVE
Dornase  alfa;
Doenc¸as
neuromusculares;
Atelectasia
Tratamento  bem  sucedido  de  atelectasia  com  Dornase  alfa  num  doente  com  distroﬁa
muscular  congénita
Resumo  Um  doente  neuromuscular  crónico  de  28  anos  de  idade,  tratado  com  ventilac¸ão
noturna  não  invasiva,  desenvolveu  atelectasia  lobar  pulmonar  e  hipoxemia  diurna.  Foi  inici-urante  24  horas,  enquanto  uma  ajuda  mecânica  para  a  tosse  eraado suporte  de  oxigénio  d
aplicada por  7  dias.  Nos  3  dias  seguintes  o  tratamento  com  Dornase  alfa  nebulizado  (rgDNase)
b.i.d. foi  testado,  sem  qualquer  melhoria  signiﬁcativa.  No  11.◦ e  13.◦ dias  rhDNase  foi  intro-
duzido por  broncoscopia  ﬂexível.  Um  restabelecimento  rápido  da  atelectasia  foi  observado
com alívio  da  hipoxemia,  sem  efeitos  secundários  signiﬁcativos.  No  16.◦ dia  o  doente  teve  alta
sem necessidade  de  oxigénio.  Em  doentes  neuromusculares  não  intubados,  com  atelectasia,
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que  não  respondam  positivamente  a  tratamentos  não  invasivos,  a  introduc¸ão  intrabronquial  de
rhDNase pode  com  seguranc¸a ajudar  a  melhorar  a  abertura  das  vias  respiratórias.
© 2012  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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cough  with  an  In-Exsufﬂator  at  pressures  of  +40/−45 cm
H2O,  delivered  respectively  over  3  and  over  2  s,  with  an
abdominal  thrust  timed  to  the  exsufﬂation  cycle.  This  pro-
tocol  was  applied  4  times/day;  additionally,  In-ExsufﬂatorIntroduction
In  neuromuscular  disease,  impairment  of  cough  mechanisms
due  to  expiratory  muscle  weakness  can  favor  the  develop-
ment  of  atelectasis  after  pulmonary  infections.1 This  can
lead  to  hypoxia  with  a  life-threatening  clinical  situation.
There  is  a  lack  of  evidence-based  studies  on  the
management  of  infectious  atelectasis.2 Although  chest
physiotherapy,  mechanical  in-exsufﬂation  (MI-E)  and  high-
frequency  chest  wall  oscillation  (HFCWO)  improve  airway
clearance,3--6 they  may  not  be  sufﬁcient,  particularly  when
secretions  become  highly  viscous  due  to  accumulation  of
signiﬁcant  amounts  of  extracellular  DNA.
Recombinant  human  Dornase  alpha  (rhDNase)  may  cleave
and  depolymerize  extracellular  DNA,  and  separate  it  from
proteins:  this  allows  endogenous  proteolytic  enzymes  to
break  proteins  and  decrease  viscoelasticity  and  surface  ten-
sion  of  purulent  sputum.  In  patients  with  cystic  ﬁbrosis
rhDNase  has  proved  extremely  effective,  with  both  aerosol
administration7 and  bronchoscopic  instillation.8 Studies  in
newborns  or  in  children  have  reported  beneﬁcial  effects
of  rhDNase  on  atelectasis  in  non-cystic  ﬁbrosis  patients,9,10
and  anecdotal  reports  have  suggested  a  beneﬁcial  effect  in
respiratory  syncytial  virus  bronchiolitis11 and  in  atelectasis
due  to  mucus  plugs  in  newborns  and  children.12
Most  of  these  studies  were  performed  by  instillating
the  drug  directly  into  the  trachea  in  intubated  patients.
Although  most  patients  showed  an  improvement  within  24  h,
in  some  of  them  direct  instillation  resulted  in  clinical  dete-
rioration,  presumably  due  to  a  mucus  mobilization  that
was  too  rapid.10 This  effect  may  be  dangerous  in  neuro-
muscular  patients  if  means  for  removal  of  the  mucus  are
not  immediately  available,  or  if  the  rate  of  mobilization
exceeds  capacity  of  elimination.  However,  no  studies  repor-
ting  effects  of  rhDNase  in  neuromuscular  patients  have  been
published.  In  this  article  we  describe  the  favorable  clinical
course  of  a  non-intubated  neuromuscular  patient  with  infec-
tious  atelectasis  treated  with  bronchoscopic  instillation  of
rhDNase.
Case report
A  female  patient  with  a  congenital  muscular  dystrophy  had
been  treated  with  nocturnal  nasal  noninvasive  positive  pres-
sure  ventilation  (NIV)  since  she  was  20.  At  the  age  of  26
she  was  hospitalised  for  a  complete  atelectasis  of  the  right
lower  lobe,  and  had  recovered  after  more  than  a  month
with  the  application  of  an  intensive  combined  protocol  of
HFCWO  (The  Vest  Airway  Clearance  System,  Hill-Rom  St.
Paul,  MN,  USA)  plus  manual  and  mechanical  assist  cough  (In-
Exsufﬂator,  Cough-Assist®,  Philips  Respironics,  Murrysville,
PA,  USA).  Her  clinical  condition  remained  good  until  the  age
F
rf  28,  when  her  lung  function  tests  showed  the  following
alues:  vital  capacity  0.55  L  (16%  of  the  predicted  value),
aximal  inspiratory  pressure  10  cmH2O  (11%  of  predicted),
aximal  expiratory  pressure  14  cmH2O  (13%  of  predicted),
nd  peak  cough  expiratory  ﬂow  80  L/min.  A  few  months
ater,  due  to  the  appearance  of  fever  and  copious  mucus
roduction,  she  was  treated  with  manual  and  mechanical
hest  physiotherapy  plus  antibiotics  (ceftriaxone)  initially.
owever,  she  still  complained  of  dyspnea  and  a  feeling  of
etained  secretions,  and  was  then  admitted  to  hospital.
he  had  a  severe  left  convex  scoliosis  with  a  mean  Cobb
ngle  of  over  70◦.  After  a  chest  X-ray,  a  CT  scan  was  per-
ormed  (Fig.  1)  which  showed  atelectasis  of  the  right  lower
obe.  Her  diurnal  arterial  oxygen  saturation  (SpO2)  ﬂuctu-
ted  between  82  and  85%  in  room  air,  while  PaCO2 was
ormal.  The  patients  showed  minimal  clinical  signs  of  dehy-
ration,  namely  dry  mouth.  She  had  good  skin  turgor  and
ormal  urine  output.  Haematocrit  and  electrolytes  were
ormal  except  for  potassium  which  was  lower  than  nor-
al.  We  began  nutritional  support  and  hydration  because
he  patient  was  not  able  to  eat  and  drink  enough.  Negative
esults  were  obtained  from  sputum  cultures;  however,  intra-
enous  antibiotics  were  administered.  Twenty-four-hour  NIV
as  begun,  with  the  addition  of  oxygen  (5  L/min),  as  NIV
lone  was  not  enough  to  maintain  SpO2 above  90%.  Fifteen-
wenty  minutes  sessions  of  HFCWO  at  a  pressure  of  5  cm
2O  and  a frequency  of  12  Hz  were  performed;  each  session
as  followed  by  ﬁve  or  six  sessions  of  mechanical  assistigure  1  Chest  CT  scan  at  admission:  atelectasis  of  the  lower
ight  lobe.
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Figure  2  Chest  CT  scan  at  day  12:  partial  regression  of  the
atelectasis.
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as  used  on  demand.  Once  24-h  NIV  had  begun,  we  asked
he  patient  to  frequently  change  her  decubitus.  However,
s  she  had  a  severe  scoliosis,  she  hardly  changed  her  body
osition  tending  to  remain  on  her  right  side.  As  the  patient
emonstrated  a  modest  clinical  improvement,  we  hypoth-
sized  that  bronchial  secretions  had  a  high  concentration
f  DNA  due  to  accumulation  of  degenerated  leukocytes.
herefore,  one  week  after  admission  we  tested  rhDNase
Pulmozyme®;  Roche,  Basel,  Switzerland).  For  three  days,
.5  mg  were  delivered  twice  daily  with  a  jet  nebulizer,  using
n  in-line  nebulizer  with  NIV,  without  success.  The  next  day
exible  ﬁberoptic  bronchoscopy  (FOB)  was  performed,  dur-
ng  NIV  plus  oxygen,  to  get  a  better  evaluation  of  the  cause
f  the  obstruction  and  to  possibly  instill  rhDNase  broncho-
copically.  FOB  showed  a  lot  of  very  thick  mucus  in  the  lower
ight  lobe,  but,  due  to  its  high  viscosity,  only  a  small  amount
ould  be  removed.  Then,  a  single  dose  of  2.5  mg  rhDNase  was
nstilled  directly  over  the  affected  area.  As  the  procedure
as  performed  in  a  clinical  ward  and  the  patient  was  at  risk
f  intubation,  this  was  carried  out  together  with  an  Inten-
ivist.  Anyway,  we  had  no  complications  except  for  a  mild
ransient  decrease  in  SpO2.  The  patient  was  closely  moni-
ored  by  trained  nurses.  Copious  but  thinner  secretions  were
emoved  with  the  help  of  the  In-Exsufﬂator.  It  had  to  be  used
ix  times  in  the  ﬁrst  hour  and  three  times  in  the  second  hour
or  periods  lasting  from  1  to  2  min  to  10  or  more  consecu-
ive  minutes.  In  the  following  hours  the  In-Exsufﬂator  was
pplied  only  according  to  the  protocol  and  within  24  h  a  sig-
iﬁcant  clinical  improvement  was  evident,  with  a  reduced
eed  of  oxygen.  A  new  CT  scan  demonstrated  a  signiﬁcant
eduction  of  the  atelectatic  area  (Fig.  2).  The  treatment  was
epeated  two  days  after  the  ﬁrst  instillation  with  the  same
ose  of  the  drug,  with  a  further  clinical  improvement  that
llowed  us  to  withdraw  oxygen.  Even  after  the  second  instil-
ation,  MI-E  was  often  required,  four  times  in  the  ﬁrst  hour
nd  once  in  the  second  hour,  unlike  in  the  following  days
hen  it  was  applied  only  according  the  protocol.  Two  days
ater  the  patient  was  discharged  (Table  1).  A  month  later  the
linical  and  radiological  recovery  was  conﬁrmed  (Fig.  3).
iscussionhis  experience  illustrates  the  safety  and  efﬁcacy  of
ntrabronchial  rhDNase  treatment  in  the  management
f  infectious  atelectasis  in  a  non-invasively  ventilated
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Table  1  Relationship  of  therapeutic  measures  with  clinical  outco
Time  Mechanical  therapy  C
1--10  h  day  HFCWO  +  In-Exsufﬂator,  NIV  day  and  night  I
s
11th day  HFCWO  +  In-Exsufﬂator  NIV  day  and  night,
intrabronchial  rhDNAse
R
e
12th day  HFCWO  +  In-Exsufﬂator,  NIV  day  and  night  E
13th day  HFCWO  +  In-Exsufﬂator  NIV  day  and  night,
intrabronchial  rhDNAse
F
14--15th day  HFCWO  +  In-Exsufﬂator,  NIV  night  only  R
16th day  NIV  night  only  D
a Reduction of dyspnea, relief of sense of retained secretions.igure  3  Chest  CT  scan  one  month  after  hospital  discharge:
omplete  resolution.
euromuscular  patient  in  whom  physiotherapy  techniques
lone  did  not  produce  a  rapid  signiﬁcant  improvement.
To  the  best  of  our  knowledge,  to  date  rhDNase  has  not
een  tested  in  neuromuscular  patients.  We  initially  used  the
rug  in  a  nebulized  form,  and  switched  to  intrabronchial
nstillation  after  that  it  was  unsuccessful.  Direct  intratra-
heal  instillation  of  the  drug  appeared  to  be  far  more
mes  and  oxygen  need.
linical  outcome  Need  of  oxygen
nitial  expectoration  and  initial
ymptoms  reliefa
5  L/min  24/24  h
apid  mucus  ﬂuidiﬁcation  with  improved
xpectoration
3  L/min  24/24  h
xpectoration  of  ﬂuid  mucus  1  L/min  24/24  h
urther  elimination  of  ﬂuid  mucus  None
eduction  of  mucus  and  expectoration  None
ischarge  None
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effective  than  its  inhalation.  Actually  in  patients  on  mechan-
ical  ventilation  nebulized  administration  of  the  drug  may
result  in  a  signiﬁcant  deposition  in  the  ventilator  tubing.  As
we  continued  our  usual  physiotherapy  treatment  protocol
after  the  rhDNase  administration,  we  cannot  conﬁrm  that
the  drug  caused  the  patient’s  recovery  from  atelectasis;
however,  a  signiﬁcant  clinical  improvement  rapidly  started
only  after  the  drug  instillation.  Interestingly,  the  same
temporal  relationship  between  drug  administration  and  clin-
ical  improvement  has  been  observed  in  the  other  clinical
series.8,9 In  common  clinical  practice  FOB  itself  is  considered
a  possible  way  of  facilitating  mucus  mobilization.13 However,
a  small  randomized  controlled  trial  showed  that  it  is  no  bet-
ter  than  physiotherapy  for  resolving  lung  volume  loss.14 In
addition,  atelectasis  frequently  recurs  after  bronchoscopy.
Conversely,  since  the  drug  was  instilled  our  patient  easily
expelled  her  secretions  and  progressively  improved  with  no
side  effects  apart  from  a  mild  and  short-lived  decrease  in
SpO2.  This  treatment  was  well  tolerated  by  the  patient  who
was  not  willing  to  undergo  a  long  hospitalization.
Best  clinical  practice  in  neuromuscular  patients  usu-
ally  requires  non-invasive  means  to  manage  respiratory
complications;  however,  intrabronchial  instillation  of  rhD-
Nase  could  be  a  supplementary  method  of  treatment.  As
rhDNase  is  an  expensive  drug,  a  cost-beneﬁt  assessment
would  be  warranted.  We  cannot  accurately  estimate  how
long  the  hospital  stay  would  have  been  for  our  patient  if  rhD-
Nase  had  not  been  used.  However,  compared  to  the  previous
episode  of  atelectasis,  we  saved  19  days  of  hospitalization.
One  vial  of  the  drug  costs  43  euros,  and  two  vials  were  used
for  local  instillation.  Since  one  day’s  stay  in  our  hospital
costs  350  euros,  the  drug  would  have  been  cost-effective
even  if  the  stay  were  reduced  by  just  one  day.
In  conclusion,  treatment  with  rhDNAse  demonstrated  a
safe  option  for  this  neuromuscular  patient  with  atelectasis
who  had  not  responded  to  normal  intensive  treatment.  Bron-
choscopic  instillation  gave  the  best  results,  liquefying  secre-
tions  that  were  easily  eliminated  with  the  In-Exsufﬂator.  As
persistent  atelectasis  may  be  a  life-threatening  condition  in
neuromuscular  patients,  we  suggest  that  this  drug  should  be
considered  for  neuromuscular  patients  when  appropriate.
Further  studies  are  needed  in  order  to  conﬁrm  its  efﬁcacy
and  the  best  method  of  administration.
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